We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed at $434.03 in the latest trading session, marking a +1.86% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.33%. Meanwhile, the Dow experienced a rise of 1.08%, and the technology-dominated Nasdaq saw an increase of 0.08%.
Coming into today, shares of the world's largest biotech drugmaker had gained 13.22% in the past month. In that same time, the Medical sector lost 0.15%, while the S&P 500 gained 1.41%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on November 3, 2026. It is anticipated that the company will report an EPS of $5.72, marking a 1.42% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $9.93 billion, indicating a 3.94% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $22.94 per share and a revenue of $38.85 billion, demonstrating changes of +5.04% and +5.7%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.02% rise in the Zacks Consensus EPS estimate. Currently, Amgen is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Amgen is presently trading at a Forward P/E ratio of 18.57. This signifies a discount in comparison to the average Forward P/E of 25.3 for its industry.
One should further note that AMGN currently holds a PEG ratio of 3.12. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.76.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Amgen (AMGN - Free Report) closed at $434.03 in the latest trading session, marking a +1.86% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.33%. Meanwhile, the Dow experienced a rise of 1.08%, and the technology-dominated Nasdaq saw an increase of 0.08%.
Coming into today, shares of the world's largest biotech drugmaker had gained 13.22% in the past month. In that same time, the Medical sector lost 0.15%, while the S&P 500 gained 1.41%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on November 3, 2026. It is anticipated that the company will report an EPS of $5.72, marking a 1.42% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $9.93 billion, indicating a 3.94% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $22.94 per share and a revenue of $38.85 billion, demonstrating changes of +5.04% and +5.7%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.02% rise in the Zacks Consensus EPS estimate. Currently, Amgen is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Amgen is presently trading at a Forward P/E ratio of 18.57. This signifies a discount in comparison to the average Forward P/E of 25.3 for its industry.
One should further note that AMGN currently holds a PEG ratio of 3.12. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.76.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.